https://www.marketscreener.com/quote/stock/INNOVATION-PHARMACEUTICAL-111313705/news/Cellceutix-Phase-2b-Clinical-Trial-of-Brilacidin-Accepted-for-Oral-Presentation-at-the-European-Co-19745778/?utm_source=telegram&utm_medium=social&utm_campaign=share